Skip to main content

Epigenomics of Patient Outcomes after Subarachnoid Hemorrhage

Last modified: Mon, 08/17/2020 - 16:43

Epigenomics of Patient Outcomes after Subarachnoid Hemorrhage

Project Data

Contact Information

Main Point of Contact:

First Name: Yvette

Last Name: Conley

Credentials: PhD, FAAN

Institutional Affiliation: University of Pittsburgh

Email: yconley@pitt.edu

Study Information

Origin of Samples/Data: Human samples and/or data

Study Description: The aims of this project focus on the daily genome-wide methylomic changes that occur in DNA representing the CNS (DNA extracted from the cerebral spinal fluid (CSF) drained as standard of care) for the first 14 days after aSAH using state of the science, high-throughput, genomic based methodologies; determining if this methylomic data impacts delayed cerebral ischemia (DCI) as well as patient outcomes after aSAH.

Additional Information

Grant Number (if applicable): R01NR013610

Grant Source: NIH/NINR

Data Information

Omic Data Available: Yes

Please Specify Epigenomic: DNA methylation

Epigenomic Platform(s): Illumina Infinium 450K

Clinical and/or other data available?: Yes

Demographic information: age, sex, race

Phenotype(s): delayed cerebral ischemia; acute clinical deterioration; 3, 6, 12, and 24 month MRS and GOS outcomes

Data on additional variables: initial extent of injury/bleed (Fisher and Hunt & Hess scores)

Additional Information: Daily CSF samples (from EVD bags); DNA extracted from daily CSF samples; plasma from day closest to rupture available; DNA extracted from blood. In addition to availability of samples and data, my laboratory is also a resource for training in the use of these approaches.

Sample Information

Samples available for prospective analysis: Yes

Whole Blood: No

Saliva: No

Serum: No

Other Tissue: Yes

Specify Other Tissue: CSF; plasma

Extracted DNA: Yes

Extracted RNA: No

Other Extracted Biological Material: No

Approximate Number of Samples: 580

Additional Information: Daily CSF samples (from EVD bags); DNA extracted from daily CSF samples; plasma from day closest to rupture available; DNA extracted from blood. In addition to availability of samples and data, my laboratory is also a resource for training in the use of these approaches.